Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125612602 | 12561260 | 2 | F | 20160502 | 20160715 | 20160715 | 20160722 | EXP | US-PFIZER INC-2016337109 | PFIZER | 48.00 | YR | M | Y | 79.00000 | KG | 20160722 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125612602 | 12561260 | 1 | PS | SIROLIMUS. | SIROLIMUS | 1 | UNK | Y | 21083 | ORAL SOLUTION | |||||||||
| 125612602 | 12561260 | 2 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | 5 MG, UNK (QOD) | Y | 0 | 5 | MG | |||||||
| 125612602 | 12561260 | 3 | SS | JAKAFI | RUXOLITINIB | 1 | Oral | UNK | Y | 0 | TABLET | ||||||||
| 125612602 | 12561260 | 4 | SS | LOVENOX | ENOXAPARIN SODIUM | 1 | UNK | Y | 0 | ||||||||||
| 125612602 | 12561260 | 5 | C | NIFEDIPINE. | NIFEDIPINE | 1 | 0 | ||||||||||||
| 125612602 | 12561260 | 6 | C | METOPROLOL. | METOPROLOL | 1 | 0 | ||||||||||||
| 125612602 | 12561260 | 7 | C | ATOVAQUONE. | ATOVAQUONE | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 8 | C | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 9 | C | AZITHROMYCIN ANHYDROUS. | AZITHROMYCIN ANHYDROUS | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 10 | C | MONTELUKAST | MONTELUKAST SODIUM | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 11 | C | BUDESONIDE. | BUDESONIDE | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 12 | C | LASIX | FUROSEMIDE | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 13 | C | IMMUNOGLOBULIN | HUMAN IMMUNOGLOBULIN G | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 14 | C | POSACONAZOLE | POSACONAZOLE | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 15 | C | DITROPAN | OXYBUTYNIN CHLORIDE | 1 | UNK | 0 | |||||||||||
| 125612602 | 12561260 | 16 | C | HEPARIN | HEPARIN SODIUM | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125612602 | 12561260 | 1 | Graft versus host disease |
| 125612602 | 12561260 | 2 | Graft versus host disease |
| 125612602 | 12561260 | 3 | Graft versus host disease |
| 125612602 | 12561260 | 4 | Thrombosis prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125612602 | 12561260 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125612602 | 12561260 | Abscess limb | |
| 125612602 | 12561260 | Anaemia | |
| 125612602 | 12561260 | Anxiety | |
| 125612602 | 12561260 | Aspartate aminotransferase increased | |
| 125612602 | 12561260 | Back pain | |
| 125612602 | 12561260 | Bacteraemia | |
| 125612602 | 12561260 | Bacterial disease carrier | |
| 125612602 | 12561260 | Burning sensation | |
| 125612602 | 12561260 | Colonic pseudo-obstruction | |
| 125612602 | 12561260 | Diarrhoea | |
| 125612602 | 12561260 | Dyspnoea | |
| 125612602 | 12561260 | Encephalitis meningococcal | |
| 125612602 | 12561260 | Graft versus host disease | |
| 125612602 | 12561260 | Groin pain | |
| 125612602 | 12561260 | Haematoma | |
| 125612602 | 12561260 | Haematuria | |
| 125612602 | 12561260 | Hepatic enzyme abnormal | |
| 125612602 | 12561260 | Hypercalcaemia | |
| 125612602 | 12561260 | Hyperglycaemia | |
| 125612602 | 12561260 | Hypernatraemia | |
| 125612602 | 12561260 | Hypertension | |
| 125612602 | 12561260 | Hypoaesthesia | |
| 125612602 | 12561260 | Hypokalaemia | |
| 125612602 | 12561260 | Hypophosphataemia | |
| 125612602 | 12561260 | Leukocytosis | |
| 125612602 | 12561260 | Mental status changes | |
| 125612602 | 12561260 | Metabolic acidosis | |
| 125612602 | 12561260 | Muscular weakness | |
| 125612602 | 12561260 | Pain | |
| 125612602 | 12561260 | Pain in extremity | |
| 125612602 | 12561260 | Pleural effusion | |
| 125612602 | 12561260 | Pneumonia pseudomonal | |
| 125612602 | 12561260 | Posterior reversible encephalopathy syndrome | |
| 125612602 | 12561260 | Psoas abscess | |
| 125612602 | 12561260 | Pyrexia | |
| 125612602 | 12561260 | Respiratory failure | |
| 125612602 | 12561260 | Rhabdomyolysis | |
| 125612602 | 12561260 | Systemic inflammatory response syndrome | |
| 125612602 | 12561260 | Tachycardia | |
| 125612602 | 12561260 | Toxicity to various agents | |
| 125612602 | 12561260 | Varicella zoster virus infection | |
| 125612602 | 12561260 | White blood cell count increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125612602 | 12561260 | 1 | 20160510 | 0 | ||
| 125612602 | 12561260 | 2 | 20160510 | 0 | ||
| 125612602 | 12561260 | 3 | 20160510 | 0 | ||
| 125612602 | 12561260 | 4 | 20160510 | 0 | ||
| 125612602 | 12561260 | 7 | 20160511 | 0 | ||
| 125612602 | 12561260 | 11 | 20160511 | 0 | ||
| 125612602 | 12561260 | 14 | 2012 | 20160320 | 0 | |
| 125612602 | 12561260 | 15 | 20160511 | 0 |